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Abstract 
This study was to investigate the quinolone resistance to gram negative bacteria isolated in the First Bethune Hospital 
during the past 8 years. Disk diffusion test was used to study the antimicrobial resistance. The data were analyzed by 
WHONET 5 software according to Clinical and Laboratory Standards Institute(CLSI). The rates of extended 
spectrum beta-lactamases˄ ESBLs  ˅ in Escherichia coli and Klebsiella.spp were 43.6ˁ~60.1ˁ and 51.0ˁ~65.1ˁ 
during the past 8 years, respectively. In recent 8 years, the quinolone resistance to gram negative bacteria  had 
increased. In particular, Escherichia coli resistant to quinolones was more obvious. Monitoring of the quinolone 
resistance to gram negative bacteria should be strengthened. The change of the antimicrobial resistance should be 
investigated in order to guide direct rational drug usage in the clinic and prevent bacterial strain of drug resistance 
from being transmitted. 
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1. Introduction 
High prevalences of quinolone resistance in enterobacteria, particularly in Escherichia coli, have been 
described in America and Asia[1-2]. In Escherichia coli and klebsiella, quinolone resistance has been 
more frequently found among strains producing plasmid-mediated ESBLs than among ESBLs-negative 
strains, which maybe related to the coordinated expression of several mechanisms of resistance.The 
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objectives of this study were to investigate the quinolone resistance to gram negative bacteria in 8 
consecutive years in our hospital. 
2. Materials And Methods 
2.1 Bacterial isolates 
Consecutive nonduplicate nosocomial isolates of gram negative bacteria were collected during the 
period from 2003 to 2010 in our hospital. Isolates were identified at the species level using standard 
biochemical tests and microbiological methods. 
2.2 Antimicrobial susceptibility testing 
The susceptibilities of gram negative bacteria to 3 quinolone agents were determined by the disk 
diffusion method in accordance with the Clinical and Laboratory Standards Institute(CLSI) guidelines. 
2.3 Detection of ESBLs production 
ESBLs production was detected using the double-disk synergy (DDS) test. ESBLs presence was 
assayed using the following antibiotic disks (OXOID): cefotaxime (30 ȝg), cefotaxime/clavulanic acid 
(30/10 ȝg), ceftazidime (30 ȝg), and ceftazidime/clavulanic acid (30/10ȝg). A 5-mm increase in a zone 
diameter for either antimicrobial agent tested in combination with clavulanic acid vs its zone when tested 
alone was ESBLs production. Klebsiella pneumoniae ATCC 700603 and Escherichia coli ATCC 25922 
and ATCC 35218 strains served as quality controls.  
3. Results 
The rates of ESBLs in Klebsiella.spp are 51.0ˁ(74/145), 51.2ˁ(83/162), 51.2ˁ(86/168), 65.1ˁ
(114/175), 52.6ˁ(100/190), 54.9ˁ(377/687), 51.8ˁ(400/772), 54.1ˁ(460/850),from 2003 to 2010, 
respectively. The rates of ESBLs in Escherichia coli are 43.6ˁ˄146/335˅, 50.9ˁ˄192/377˅, 54.9ˁ
˄248/452 ,˅ 60.1ˁ˄ 182/303 ,˅ 48.6ˁ˄ 226/465 ,˅ 50.8%(667/1312), 50.9%(751/1476), 50.3%(819/1629) 
from 2003 to 2010, respectively. 
Resistance of pseudomonas aeruginosa, Acinetobacter baumanii, ESBLs-positive and –negative 
Klebsiella.spp and Escherichia coli isolates to quinolone is shown in table 1. 
4. Discussion 
The current study showed prevalence of ESBLs-production range from 51.0ˁ̚65.1ˁ,43.6%̚
60.1% in Klebsiella.spp and Escherichia coli in our hospital, respectively. The resistance rates of 
ESBLs-producing Klebsiell.spp to quinolone were much higher than those of non-ESBLs-producing 
Klebsiell.spp and Escherichia coli in 8 consecutive years in our hospital. ESBLs producers are commonly 
resistant to different antibiotic families including quinolones. Our study showed the resistance rates of 
pseudomonas aeruginosa and Acinetobacter baumanii to quinolone were also very high in our hospital. 
Broad use of quinolones has been followed by emergence of resistance, which has been due mainly to 
chromosomal mutations in genes encoding the subunits of the drugVĄtarget enzymes, DNA gyrase and 
topoisomerase IV, and in genes that affect the expression of diffusion channels in the outer membrane and 
multidrug-resistance efflux systems. Recently, qnr genes, aac(6Ą)-Ib-cr gene, quinolone efflux pump 
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protein QepA have involved. The mainly reason for high resistance to quinolone is the selection and 
persistence of multidrug-resistant ESBLs strains and plasmids in both clinical and community 
settings[3].It is alerted that too much quinolone have been used in China. 
Monitoring antibiotic use with microbiology laboratory support can promote rational drug utilization, 
cut costs and delay the emergence of resistant organisms. 
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TABLE 1  Resistance of common pathogenic bacteria to quinolone (%) 
bacteria year isolates CIP LEV GAT bacteria year isolates CIP LEV GAT
pseudomonas 
aeruginosa 
2003 90 18.9 13.3 11.1
ESBLs+
Escherichia
coli 
2003 146 74.7 73.3 67.1
 2004 110 18.2 13.6 12.7  2004 192 75.0 75.5 68.8
 2005 128 21.1 15.9 15.6  2005 248 79.8 76.6 68.5
 2006 150 26.7 28.7 23.3  2006 182 76.4 74.7 71.4
 2007 178 34.2 33.1 31.5  2007 226 77.0 76.1 70.4
 2008 560 35.7 32.1 28.8  2008 667 78.0 74.9 72.0
 2009 610 39.3 31.1 29.7  2009 751 79.9 75.9 73.2
 2010 710 40.8 35.2 33.8  2010 819 78.1 74.5 73.3
Acinetobacter 
baumanii 
2003 80  28.8 19.0 21.3 ESBLs-
Klebsiella.spp 2003 71 18.3 15.5 12.6
 2004 100 31.0 19.0 21.0  2004 79 20.3 17.7 13.9
 2005 106 33.3 22.6 23.1  2005 82 22.0 17.1 14.8
 2006 122 37.7 31.1 26.2  2006 61 21.3 19.7 16.3
 2007 155 45.2 39.4 29.0  2007 90 22.2 18.0 16.0
 2008 501 51.9 39.9 29.9  2008 310 21.3 19.4 17.4
 2009 612 58.8 42.5 32.7  2009 372 24.2 21.5 18.8
 2010 699 60.1 50.1 35.6  2010 390 25.1 21.8 20.5
ESBLs-
Escherichia
coli 
2003 189 59.3 56.1 50.8 ESBLs+
Klebsiella.spp 2003 74 33.8 25.7 20.3
 2004 185 58.9 55.1 51.4  2004 83 38.6 34.9 20.5
 2005 204 62.4 57.4 50.5  2005 86 46.5 37.2 35.2
 2006 121 57.0 51.2 50.4  2006 114 41.2 36.8 34.2
 2007 239 60.3 59.0 50.6  2007 100 43.0 37.0 35.0
 2008 645 62.0 55.8 54.3  2008 377 47.7 37.1 34.7
 2009 725 62.1 55.2 53.8  2009 400 48.8 47.5 45.0
 2010 810 61.7 55.6 54.3  2010 460 52.2 50.0 47.8
 
Note: CIP: ciprofloxacin, LEV: levofloxacin, GAT: gatifloxacin 
